FDA inspection
Covidien Llc: FDA inspection ending Feb 14, 2006
FDA inspection 414497 · No Action Indicated (NAI) · Mansfield, MA
Key facts
| Inspection ID | 414497 |
|---|---|
| Firm | Covidien Llc |
| FEI number | 1282497 |
| Address | 15 Hampshire St |
| City | Mansfield |
| State | MA |
| ZIP | 02048-1113 |
| Fiscal year | 2006 |
| Inspection end date | Feb 14, 2006 |
| Classification | No Action Indicated (NAI) |
| Project area | Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Drug Quality Assurance|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs|Post Mrkt Surv & Epid: Human Drugs |
| Product type | Drugs |
At a glance
- None Citations
- None Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 10–99 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data